

Case Report

Open Access

Cryptogenic hepatic insult, failing heart and advancing age: a case report

Akansha Agrawal, Manish Soneja, Ashish Goel*, H Pati and Aparajit B Dey

Address: Department of Medicine, All India Institute of Medical Sciences, ND 110029, India

Email: Akansha Agrawal - akansha.a@gmail.com; Manish Soneja - manish733@yahoo.com; Ashish Goel* - ashgoe@yahoo.com; H Pati - harappati@yahoo.co.in; Aparajit B Dey - abdey@hotmail.com

* Corresponding author

Published: 19 December 2008

Received: 11 September 2008

Cases Journal 2008, 1:408 doi:10.1186/1757-1626-1-408

Accepted: 19 December 2008

This article is available from: <http://www.casesjournal.com/content/1/1/408>

© 2008 Agrawal et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Weakness and fatigue are accepted as normal accompaniments of aging. Usually, older individuals are not investigated with much enthusiasm but a treatable cause is discernible on several occasions.

Case presentation: We had a 67 year old hypertensive lady with a mitral stenosis, presenting in ischemic or hypertensive heart failure with underlying valvular disease, without pulmonary hypertension in sinus rhythm. She had pancytopenia with severe anemia and raised liver enzymes. Bone marrow examination showed aplastic anemia. She was treated with ATG and improved subsequently to become transfusion free. However, she succumbed to an unrelated sudden cardiac death.

Conclusion: Our patient is unique in her uncommon presentation, complex management issues and a favorable outcome after a long and persevering therapeutic intervention and finally her sudden death.

Case report

In December, 2007 a 67 year old hypertensive lady, with a known rheumatic mitral stenosis, presented with insidious onset, gradually progressive fatigue of one month, which had decompensated acutely. There was no history of peptic ulcer, use of NSAIDs or change in bowel habits. She had no previous blood transfusions or jaundice. She denied smoking or taking alcohol. There was no suggestion of long standing liver or kidney disease, diarrhea or infection. She took amlodipine and atenolol for hypertension. There was no history of intake of any other drugs that could have had a toxic potential.

She was pale, anicteric, normotensive and tachypneic with pulse of 100/minute. Her neck veins were engorged and she had pedal edema. She was afebrile, did not have any clubbing, and had no signs of rheumatic activity or infective endocarditis. She had a loud first heart sound, a normal second heart sound, an opening snap and a mid-diastolic murmur at apex. She had a resonant percussion note, equal air entry, and vesicular breath sounds on both sides. Coarse rales were heard in the infrascapular and infraaxillary areas. She had an enlarged tender, firm liver with sharp margins and a span of 10 cms. No splenomegaly or ascites were noted. Here, we had an old hyperten-

sive lady with a mitral stenosis, presenting in ischemic or hypertensive heart failure with underlying valvular disease, without pulmonary hypertension, rheumatic activity or infective endocarditis in sinus rhythm. An infective pathology causing acute deterioration or a pulmonary embolism was also considered.

Her hemoglobin was 65 g/L, TLC $3.2 \times 10^9/L$ with absolute neutrophils count of $1.6 \times 10^9/L$, platelet count of $43 \times 10^9/L$ and MCV 110 fL (see figure 1). Macrocytosis, hypochromia, leukopenia and reduced platelets but no abnormal cells were seen. Blood cultures were sterile. She had raised serum bilirubin (2 mg/dL) and liver enzymes (SGPT 877 and SGOT 1179 IU). Serology for hepatitis virus A, B, C, E and HIV was negative. Coombs test and antinuclear antibodies were negative. Serum vitamin B₁₂ level was 896 pg/ml.

Echocardiography showed mild mitral stenosis (MVOA 1.8 sqcm) with normal left ventricular ejection fraction, and no signs of infective endocarditis. Serum and urine electrophoresis did not detect any abnormal bands. Bone marrow biopsy from the iliac crest showed profound hypoplasia with overall cellularity of less than 5%. She had osteoporosis with a bone mineral density of 0.714 g/sqcm. Her liver function tests rapidly returned to normal levels.




Figure 1
Distribution of hemoglobin level, platelet count and total leukocyte counts over time. To represent comparative patterns of platelets, hemoglobin and leukocyte count in the same figure, the platelet count has been represented as actual count $\times 10^{-4}$, leukocyte count has been represented as actual count $\times 10^{-3}$ and the hemoglobin has been represented as its actual value.

She was given immunosuppression with anti-thymocyte globulin at the dose of 40 mg/kg daily for 4 days along with prednisolone at 1 mg/kg tapered over 3 weeks. This was followed by cyclosporine at the dose of 10 mg/kg/day. The patient continued to need regular and frequent blood and component transfusion support for ten more weeks. The profile of her hematological parameters over this period is reflected in table 1. When seen in April, she was doing well and had been transfusion free for three weeks. She subsequently remained free of complications for another month, but then she complained of acute abdominal pain and succumbed before she could be taken to the hospital for medical attention suspected to have had an unrelated sudden cardiac death. A post mortem examination could not be performed.

Weakness and fatigue are accepted as normal accompaniments of aging. Usually, older individuals are not investigated with much enthusiasm but a treatable cause is discernible on several occasions. Here, anemia with CHF was evident at presentation. Chronic disease, iron deficiency, vitamin B₁₂ or folate deficiency, gastrointestinal bleeding and myelodysplastic syndrome are commonly identified.[1] Aplastic anemia, remains rare in older persons. Older patients are usually ineligible for allogeneic bone marrow transplantation, owing to absence of a donor, advanced age and frail phenotype. Immunosuppression with cyclosporin and antithymocyte globulin (ATG) is often contemplated but infrequently tried in older individuals.[2,3] It is known that 50% younger patients respond within 3 months of immunosuppression, and about 75% by 6 months, and become transfusion independent, but some may have a persistently hypoproliferative marrow. In the current case, bone marrow suppression followed a transient cryptogenic hepatitis, likely of a viral etiology. Aplastic anemia has been reported between 3–6 months following cryptogenic hepatitis in younger patients.[4,5] A more protracted course might be seen in older patients following immunosuppression. Our patient is unique in her uncommon presentation, complex management issues and a favorable outcome after a long and persevering therapeutic intervention and finally her sudden death.

Consent

Consent could not be taken from the patient before publication because she expired before this could be done. Care has been taken to preserve the confidentiality of patient identity

Competing interests

The authors declare that they have no competing interests.

Table 1: Progression of the hematological parameters of the patient over time

Date	Hemoglobin	Platelet Count	Total Leukocyte Count
30.10.07	9.6	.	7200
11.12.07	6	.	.
12.12.07	5.3	5000	3620
13.12.07	6.9	34000	3400
14.12.07	7.4	40000	2500
15.12.07	6.2	28000	4200
16.12.07	8.5	40000	4000
19.12.07	11.9	.	5500
20.12.07	11.8	10000	3800
21.12.07	10.5	16000	4400
22.12.07	10.8	18000	2900
23.12.07	7.9	17000	4800
24.12.07	9	17000	3200
26.12.07	9.3	26000	2100
27.12.07	7.8	20000	2400
29.12.07	8.3	122000	1600
31.12.07	7.4	88000	1900
14.01.08	8.6	61000	2800
18.01.08	7.8	61000	3100
22.01.08	7.5	24000	4130
24.01.08	9.2	17000	3500
27.01.08	9.4	25000	4400
28.01.08	10.1	15000	5100
31.01.08	8.4	15000	2000
02.01.08	7.7	57000	1900
15.02.08	5.8	13000	7540
17.02.08	8.7	34000	3800
19.02.08	7.7	43000	6130

Table 1: Progression of the hematological parameters of the patient over time (Continued)

23.02.08	6.9	18000	5970
26.02.08	6.6	19000	3920
29.02.08	8.9	16000	.
03.01.08	7.4	45000	4200
03.03.08	.	20000	.
14.03.08	11	34000	5000
17.03.08	11.4	40000	8040
04.01.08	6.8	68000	4500
04.02.08	8.7	40000	5500
06.01.08	6.7	13000	1200
07.01.08	6.2	124000	1900
07.03.08	8	19000	8900
08.02.08	7.7	10000	5100
09.01.08	6.4	10000	1800
09.02.08	7.2	6000	3700
10.01.08	6.4	19000	2300
10.03.08	7.3	17000	3670
11.01.08	10.2	19500	4600
11.02.08	8.2	56000	4320
12.03.08	11.6	40000	.

Authors' contributions

AA and MS were involved with the day to day management of the patient. AG supervised patient management and completed the final draft of the manuscript. HP was involved in coordinating the pathology reports and arriving at a diagnosis for the patient. ABD held the over all responsibility of patient care and took the final decisions regarding management

References

- Smith DL: **Anemia in the elderly.** *Am Fam Physician* 2000, **62(7)**:1565-72.
- Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, et al.: **Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with non-severe aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party.** *Blood* 1999, **93(7)**:2191-5.
- Zheng Y, Liu Y, Chu Y: **Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens.** *Exp Hematol* 2006, **34(7)**:826-31.
- Kayashima S, Kondou T, Watanabe Y, Kobari S, Kagami M: **A patient with non-A, non-B, non-C hepatitis-associated aplastic anemia recovered promptly following immuno-suppressive therapy, including antithymocyte globulin.** *Int J Hematol* 1998, **67(4)**:403-9.
- Adachi Y, Usuki K, Kazama H, Iki S, Matsuya S, Urabe A: **[Successful combined therapy with ATG, cyclosporin and G-CSF for both liver dysfunction and bone marrow failure in hepatitis-associated aplastic anemia].** *Rinsho Ketsueki* 2001, **42(9)**:691-5.